Key facts
- It has raised $11.2M across 5 recorded rounds; the latest was Seed Round ($1.9M) in Dec 2023.
- Notable investors include National Institutes of Health, TEDCO, CARB-X, Ecphora Capital, Lung — 10 tracked in total.
- Novel Microdevices has filed 10 Form Ds with the SEC since 2020, most recently Jan 2025 ($567K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Novel Microdevices
Funding rounds
5 roundsAbout Novel Microdevices
Developer of a handheld point-of-care medical device designed to facilitate molecular diagnostics. The company's device uses microfluidics to analyze a raw biological sample directly at the point of care and takes only half an hour to interpret quality results, enabling healthcare professionals to ensure accurate results in a lab-free environment.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2014
- Employees
- 40
- Website
- noveldx.com/
- Ownership
- Privately Held (backing)
Novel Microdevices doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Novel Microdevices shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Novel Microdevices in its N-PORT filings yet. We sweep new filings monthly.